EIGR vs. KRBP, ELOX, GMDA, WINT, FNCH, ALBT, NSTGQ, ACOR, TCBP, and SCNI
Should you be buying Eiger BioPharmaceuticals stock or one of its competitors? The main competitors of Eiger BioPharmaceuticals include Kiromic BioPharma (KRBP), Eloxx Pharmaceuticals (ELOX), Gamida Cell (GMDA), Windtree Therapeutics (WINT), Finch Therapeutics Group (FNCH), Avalon GloboCare (ALBT), NanoString Technologies (NSTGQ), Acorda Therapeutics (ACOR), TC Biopharm (TCBP), and Scinai Immunotherapeutics (SCNI). These companies are all part of the "medical" sector.
Eiger BioPharmaceuticals (NASDAQ:EIGR) and Kiromic BioPharma (NASDAQ:KRBP) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, profitability, risk, institutional ownership, dividends, media sentiment, valuation and earnings.
Eiger BioPharmaceuticals received 413 more outperform votes than Kiromic BioPharma when rated by MarketBeat users. Likewise, 67.87% of users gave Eiger BioPharmaceuticals an outperform vote while only 50.00% of users gave Kiromic BioPharma an outperform vote.
Eiger BioPharmaceuticals has a beta of 1.83, suggesting that its share price is 83% more volatile than the S&P 500. Comparatively, Kiromic BioPharma has a beta of 2, suggesting that its share price is 100% more volatile than the S&P 500.
Kiromic BioPharma has lower revenue, but higher earnings than Eiger BioPharmaceuticals. Kiromic BioPharma is trading at a lower price-to-earnings ratio than Eiger BioPharmaceuticals, indicating that it is currently the more affordable of the two stocks.
62.5% of Eiger BioPharmaceuticals shares are held by institutional investors. Comparatively, 10.9% of Kiromic BioPharma shares are held by institutional investors. 4.2% of Eiger BioPharmaceuticals shares are held by company insiders. Comparatively, 3.3% of Kiromic BioPharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
In the previous week, Eiger BioPharmaceuticals had 1 more articles in the media than Kiromic BioPharma. MarketBeat recorded 1 mentions for Eiger BioPharmaceuticals and 0 mentions for Kiromic BioPharma. Eiger BioPharmaceuticals' average media sentiment score of 0.02 beat Kiromic BioPharma's score of 0.00 indicating that Eiger BioPharmaceuticals is being referred to more favorably in the media.
Eiger BioPharmaceuticals presently has a consensus target price of $120.00, indicating a potential upside of ∞. Given Eiger BioPharmaceuticals' higher possible upside, analysts clearly believe Eiger BioPharmaceuticals is more favorable than Kiromic BioPharma.
Kiromic BioPharma has a net margin of 0.00% compared to Eiger BioPharmaceuticals' net margin of -590.80%. Kiromic BioPharma's return on equity of 0.00% beat Eiger BioPharmaceuticals' return on equity.
Summary
Eiger BioPharmaceuticals beats Kiromic BioPharma on 11 of the 16 factors compared between the two stocks.
Get Eiger BioPharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for EIGR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EIGR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eiger BioPharmaceuticals Competitors List
Related Companies and Tools
